Login to Your Account

Clinic Roundup

Thursday, April 7, 2011
• Avila Therapeutics Inc., of Waltham, Mass., reported that it completed two Phase Ia clinical studies for AVL-292, its orally available, selective inhibitor of Bruton's tyrosine kinase. Avila presented summary results from the first-in-human study, AVL-292-001, at the Keystone Symposium on Molecular and Cellular Biology. In the double-blind, placebo-controlled, single ascending dose study in healthy volunteers, AVL-292-001 demonstrated favorable safety, tolerability and pharmacokinetics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription